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Background. Aspergillus flavus is one of the most common agents of invasive aspergillosis and is associated with high mortality. 
The orotomides are a new class of antifungal agents with a novel mechanism of action. An understanding of the pharmacodynamics 
(PD) of the lead compound F901318 is required to plan safe and effective regimens for clinical use.
Methods. The pharmacokinetics (PK) and PD of F901318 were evaluated by developing new in vitro and in vivo models of inva-
sive fungal sinusitis. Galactomannan was used as a pharmacodynamic endpoint in all models. Mathematical PK-PD models were 
used to describe dose-exposure-response relationships.
Results. F901318 minimum inhibitory concentrations (MICs) ranged from 0.015 to 0.06 mg/L. F901318 induced a concentra-
tion-dependent decline in galactomannan. In the in vitro model, a minimum concentration:MIC of 10 resulted in suppression of 
galactomannan; however, values of approximately 10 and 9–19 when assessed by survival of mice or the decline in galactomannan, 
respectively, were equivalent or exceeded the effect induced by posaconazole. There was histological clearance of lung tissue that was 
consistent with the effects of F901318 on galactomannan.
Conclusions. F901318 is a potential new agent for the treatment of invasive infections caused by A flavus with PDs that are com-
parable with other first-line triazole agents.
Keywords: Aspergillus flavus; in vivo; orotomides; pharmacodynamics; pharmacokinetics.
 
Aspergillus flavus is one of the most common causes of both 
invasive and noninvasive fungal rhinosinusitis [1–5]. Acute 
invasive fungal rhinosinusitis is a relatively uncommon, but 
rapidly progressive lethal disease with mortality rates of 20%–
80% [6–9]. Treatment requires early aggressive antifungal 
therapy. Surgical debridement may also be required [5, 6, 8]. 
Voriconazole or a lipid formulation of amphotericin B are first-
line antifungal agents for treatment of acute invasive sinusitis 
[10]. Triazole resistance is being increasingly reported in clini-
cal strains of A flavus [11–16]. As a result, new antifungal agents 
are urgently required.
F901318 (F2G Ltd., Eccles, UK) is the lead compound of the 
orotomides, which is a new antifungal class. F901318 reversibly 
inhibits dihydroorotate dehydrogenase and interferes with 
pyrimidine biosynthesis. Potent in vitro and in vivo activity has 
been demonstrated against a wide spectrum of pathogenic fil-
amentous fungi including Penicillium spp, Coccidiodes immitis, 
Histoplasma capsulatum, Blastomyces dermatitidis, Fusarium 
spp, Scedosporium spp, and Aspergillus spp such as Aspergillus 
fumigatus and A flavus [17, 18].
In this study, we describe the pharmacodynamics (PD) of 
F901318 against A flavus. We developed new in vitro models of 
acute invasive sinusitis that enabled the PD of voriconazole and 
F901318 to be elucidated. A murine model of sinopulmonary 
invasive aspergillosis resulting from A flavus was also devel-
oped and used to evaluate the PD of F901318. The results were 
benchmarked against the PD of posaconazole.
METHODS
Aspergillus flavus Strains and Antifungal Susceptibility Testing
Four A flavus isolates were used in this study (Table 1). 
ATCC204304 was used for the primary development of new in 
vitro models of invasive A flavus infection. An additional 3 clini-
cal A flavus isolates that had caused invasive disease were selected 
from the Special Mycology Laboratory (LEMI) (UNIFESP, 
Brazil). LEMI764 was isolated from a skin biopsy, LEMI1024 
was isolated from a hepatic lesion, and LEMI1049 was isolated 
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from nasal mucosa. Strains were identified as A flavus sensu 
stricto based on standard morphological and molecular studies, 
including sequence analysis of the internal transcribed spacer 
region, calmodulin, and β-tubulin genes [11, 19].
Minimum inhibitory concentration (MIC) values were esti-
mated according to European Committee on Antimicrobial 
Susceptibility Testing and Clinical Laboratory Standards Institute 
methodologies [20, 21]. Compound with >98% purity was used 
for susceptibility testing. All susceptibility tests were performed 
as 10 independently conducted experiments for posaconazole 
(Sigma-Aldrich, Dorset, UK), voriconazole (Sigma-Aldrich, 
Dorset, UK), and F901318 (F2G Ltd., Manchester, UK).
Development of a Cellular Bilayer Model of Human Nasal Epithelium
A previously described in vitro model of the human alveolus was 
modified to simulate acute invasive sinusitis caused by A flavus [22, 
23]. A cellular bilayer with human nasal epithelial cells ([HNECs] 
Promocell, Heidelberg, Germany) and human pulmonary artery 
endothelial cells ([HPAECs] Promocell) was constructed. Human 
nasal epithelial cells were cultured into ready-to-use airway epi-
thelial cell growth medium (Promocell). The HPAECs were 
cultured in endothelial growth medium ([EGM]-2), prepared 
according to the manufacturer’s instructions (amphotericin B and 
gentamicin were not added). Cells were incubated at 37˚C in 5% 
CO2. Once confluence was achieved, cells were washed twice with 
Hanks Balanced Salt Solution (Sigma-Aldrich) and harvested 
with warmed 0.25% trypsin-ethylenediaminetetraacetic solution. 
Cells were centrifuged for 5-minutes and resuspended in warmed 
media to achieve final concentrations of 1 × 106 cells/mL for both 
HNECs and HPAECs.
Cellular bilayers were constructed on ThinCert cell culture 
inserts. Different sizes of inserts were used for the static and dynamic 
models. Inserts were inverted onto glass sterile petri dishes, and 
HPAECs cells were placed on the underside of the membrane. To 
establish adherence, the inverted inserts were incubated for 2 hours 
at 37˚C in 5% CO2. Inserts were then righted and transferred to 
plates containing EGM-2 medium. After 24 hours, inserts were 
relocated to new plates with fresh EGM-2 medium and HNECs 
were seeded on the top of the membrane. The medium from the 
endothelial compartment was changed every 48 hours for 5 days. 
Accumulated medium from epithelial compartment was removed. 
The integrity of the bilayer was assessed using the translocation of 
1% Blue Dextran (Sigma-Aldrich) [22].
At the time of A flavus infection, inserts were placed into plates 
containing EBM-2 media supplemented with 2% fetal bovine 
serum (FBS) (Lonza Biologics, Basel, Switzerland). A suspension 
containing 1 × 104 conidia/mL was pipetted into the nasal epithe-
lial compartment (100 µL and 400 µL for static and dynamic exper-
iments, respectively). Inserts were incubated for 6 hours at 37˚C in 
5% CO2, after which the inoculum was removed and discarded.
To characterize the time-course of invasion, inserts were 
fixed in Cellstor pot—90  mL with 10% neutral-buffered for-
malin (CellPath, Newtown, UK) for histopathological studies. 
Sections were stained with Grocott’s Methenamine Silver stain 
using standard protocols.
Development of a Dynamic In Vitro Model of Acute Invasive Sinusitis
Custom-designed and previously described [22] stainless steel bio-
reactors were incorporated in circuits constructed with Marprene 
thermoplastic elastomer tubing (Watson Marlow, Falmouth, UK), 
Silastic, 1.6-mm bore tubing (Dow Corning, Barry, UK), and poly-
propylene barbed luer adapters (West Group, Waterlooville, UK). 
A 250-mL Duran bottle was used as a central compartment, and 
contained 200-mL warmed Dulbecco’s modified Eagle medium 
(DMEM) containing d-glucose, l-glutamine, and HEPES buffer 
(Invitrogen, Paisley, UK) supplemented with 2% FBS and penicil-
lin-streptomycin solution (Sigma). The central compartment was 
connected into the circuit with 1.5-mm bore polytetrafluoroeth-
ylene semirigid tubing (Kinesis, St Neots, UK) fitted into Omni-
Fit Q-series bottle caps (Kinesis). To ensure continuous mixing, 
Table 1. Aspergillus flavus Isolates Used in this Studya
Strain Antifungal Agent
CLSI EUCAST
Range Mode G. Mean Range Mode G. Mean
ATCC204304 Voriconazole 0.5–1 0.5 0.6 1–2 1 1.3
Posaconazole 0.06–0.125 0.125 0.09 0.06–0.25 0.125 0.12
F901318 0.008–0.03 0.008 0.011 0.03–0.06 0.03 0.03
LEMI764 Voriconazole 0.25–1 0.25 0.3 1–2 1 1.1
Posaconazole 0.03–0.125 0.06 0.06 0.125 0.125 0.125
F901318 0.008–0.015 0.015 0.01 0.015–0.06 0.03 0.027
LEMI1024 Voriconazole 0.25–1 0.5 0.6 1–2 2 1.7
Posaconazole 0.25 0.25 0.25 0.125 0.125 0.125
F901318 0.008–0.03 0.008 0.012 0.03–0.06 0.03 0.03
LEMI1049 Voriconazole 0.125–1 0.5 0.3 1–2 1 1.1
Posaconazole 0.06–0.125 0.06 0.06 0.125 0.125 0.125
F901318 0.015–0.03 0.03 0.023 0.03–0.06 0.03 0.04
Abbreviations: CLSI, Clinical Sciences Laboratory Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; G., geometric; MICs, minimum inhibitory concentrations.
aThe MICs from challenge strains used in this study. The MICs were determined in 10 independently conducted experiments according to CLSI and EUCAST methodology.
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magnetic stirring bars were used. An additional 2 Duran bottles 
were used: one containing fresh supplemented DMEM medium, 
and one empty to collect spent waste medium.
All circuits were primed with medium before use. The pump 
between central compartments and bioreactors was set to produce 
a flow rate of approximately 10 mL/hour. The pump that connected 
waste and fresh medium to the central compartment for voriconazole 
and F901318 ran at ~10 and 23 mL/hour, respectively. In both cases, 
the goal was to simulate human-like pharmacokinetics (PK).
Pharmacodynamic Experiments With Voriconazole and F901318
For PD studies in the static model, voriconazole and F901318 
were diluted in EBM-2 media supplemented with 2% FBS. 
A final volume of 600 µL per well was used in 7 different concen-
trations that ranged from 0.03 to 2 mg/L and 0.015 to 1 mg/L for 
voriconazole and F901318, respectively. Infected inserts were 
exposed to drug-containing plates for 48 hours. Subsequently, 
medium from the endothelial compartment as well as an epi-
thelial lavage with 300  µL phosphate-buffered saline was col-
lected for galactomannan estimation.
For the PD studies in the in dynamic model, target concen-
trations of 0.6, 0.25, 1, and 2 mg/L voriconazole were studied 
in addition to a drug-free control circuit. Voriconazole was 
administered at 6, 18, 30, 42, 54, and 66 hours postinoculation. 
Pharmacokinetic and PD samples were collected from taps 
inserted in each circuit between 6 and 78 hours postinoculation.
F901318 was administered as a continuous 4-hour infusion 
prepared using a β-hydroxypropyl cyclodextrin vehicle [24]. 
F901318 infusions were prepared to achieve final concentra-
tions of 0.015, 0.06, 0.25, and 1 mg/L. The PK-PD samples were 
taken between 6 and 78 hours postinoculation for all circuits.
Murine Model of Acute Sinopulmonary Aspergillosis
A new neutropenic murine model of sinopulmonary invasive asper-
gillosis caused by A flavus was developed by using galactomannan 
as the primary PD readout. Experimentation was performed under 
UK Home Office project license PPL40/3630 and had received 
approval from the Animal Welfare Ethics Review Board of The 
University of Liverpool. Male CD1 mice were purchased from 
Charles River and weighed 25–30 grams at the time of experi-
mentation. Food and water were provided ad libitum. Mice were 
rendered neutropenic with intraperitoneal injection of cyclophos-
phamide 150 mg/kg on day −4 and 100 mg/kg on day −1 relative 
to infection. Mice were further immunosuppressed with cortisone 
acetate (250 mg/kg) subcutaneously on day −1 to impair pulmonary 
macrophage function. Drinking water was supplemented with 2.5% 
enrofloxacin to prevent opportunistic bacterial infections.
For inoculation, mice were anesthetized with 2% isofluorane. 
A suspension of conidia containing 5 × 105 colony-forming units 
(CFU)/mL (50 µL/mouse of 1 × 107 CFU/mL) was instilled in 
both nares. The administration of antifungal compounds was 
delayed for 6 hours postinoculation. At predefined sampling 
times, groups of mice (n = 3) were terminally anesthetised using 
5% isofluorane, and blood was obtained via cardiac puncture. 
The lungs and nasal cavities of each of the mice were removed 
and placed in 10% neutral-buffered formalin for histopatholog-
ical analyses. Galactomannan (GM) serum indices were mea-
sured using a commercial kit (Platelia Aspergillus Kit; Bio-Rad).
In Vivo Pharmacokinetics and Pharmacodynamics of F901318
Multiple independently conducted experiments were performed 
to determine the PK-PD of F901318 against 4 strains of A flavus. 
F901318 regimens of 24 mg/kg per day, 8 mg/kg q8h, and 15 mg/
kg q8h, and a vehicle control were used. These regimens were 
chosen based on previous studies in A fumigatus [24]. A positive 
control cohort of mice that received posaconazole 20 mg/kg per 
day orally was included. Such a posaconazole regimen results in 
drug exposure that is significantly more than that achievable in 
the clinic and ordinarily results in complete suppression of the 
GM index. Mice were anaesthetized with 5% isofluorane, and 
blood was obtained via cardiac puncture. The plasma and/or 
serum was removed and stored at −80°C until future analysis. 
The plasma PK of F901318 was determined using liquid chro-
matography-tandem mass spectrometry (LC/MS/MS). For the 
PD, GM levels in serum were measured as described above.
Although voriconazole is a first-line agent for the treatment 
of all forms of invasive aspergillosis, it is notoriously difficult 
to study in mice because of its short half-life and autoinduc-
tion of clearance [25]. In contrast, posaconazole has much 
more predictable behavior with established in vivo-to-clinical 
relationships [26]. For this reason, the PD of F901318 were 
benchmarked against posaconazole, which is consistent with 
the recent approach taken by us [27]. The PK-PD relationships 
of posaconazole against A flavus were determined by studying 
the effect of 2.5, 5, 10, and 20 mg/kg per day. An area under the 
curve (AUC) of 47 mg*h/L is the upper 95% confidence bound 
of the upper quartile of response in patients with invasive asper-
gillosis receiving posaconazole as salvage therapy [28].
Survival Experiments
F901318 was administered as 24  mg q24h, 8  mg/kg q8h, and 
15 mg/kg q8h instravenously (i.v.) for 3 days. These regimens 
were based on previous studies against A fumigatus [24]. 
Posaconazole was administered as 2.5, 5, 10, and 20  mg/kg 
per day. Each cohort consisted of n = 10 mice. After treatment 
ceased, mice were observed for an additional 7 days. Mice were 
sacrificed if they were terminally unwell, could not move to 
food and water, or had lost >20% of their original body weight.
Statistical Modeling
Cox proportional hazard models were fitted to the survival 
data from mice infected with each A flavus strain and receiv-
ing F901318, and mice infected with LEMI764 and receiving 
posaconazole. The minimum blood plasma concentration 
(Cmin):minimum inhibitory concentration (MIC) and AUC 
were used as covariates to account for differences in survival 
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A B
C D
Figure 1. Invasion of the cellular bilayer by Aspergillus flavus ATCC204304. (A) At time zero, only conidia were observed in epithelial surface; (B) after 24 hours, germination 
began from the nasal epithelial surface with evidence of hyphal invasion through membrane pores and into the endothelium and endothelial compartment; (C) progressive 
fungal growth and invasion; (D) development of fruiting bodies on the epithelial surface at 72 hours postinfection. Scale bar, 25 µm (A and B) and 50 µm (C and D).
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Figure 2. Pharmacodynamics of voriconazole and F901318 against Aspergillus flavus. The pharmacodynamic readout is the galactomannan index determined using the 
Platelia kit. (A) Galactomannan index from the nasal epithelial compartment after voriconazole exposure; (B) galactomannan index from endothelial compartment after 
voriconazole exposure; (C) galactomannan index from epithelial compartment after F901318 exposure; (D) galactomannan index from endothelial compartment after F901318 
exposure. Data are the mean from 3 inserts. Error bars have been omitted for clarity.
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in each of the treatment cohorts receiving different regimens 
F901318 and posaconazole, respectively. The model took the 
form λ λt t X( ) = ( )0 exp( )γ , where λ t( ) is the hazard, λ0 t( ) is 
the baseline hazard, X is the covariate. The function exp( )γ  pro-
vides an estimate of the hazard ratio.
Bioanalysis via Liquid Chromatography-Tandem Mass Spectrometry 
Antifungal drug concentrations from in vitro and in vivo samples 
were measured using LC/MS/MS with an Agilent 6420 Triple 
Quad Mass spectrometer and Agilent 1290 infinity LC system 
(Agilent Technologies UK Ltd, Cheshire, UK). Drug concentra-
tions were measured in cell culture medium (voriconazole and 
F901318) and mouse plasma (posaconazole and F901318). The 
assays are described in detail in Supplementary Data.
Pharmacokinetics and Pharmacodynamic Mathematical Modeling
The PK-PD mathematical model was fitted to the data using 
the population PK program Pmetrics [29]. In these analyses, an 
“individual” consisted of a cohort of mice receiving a given reg-
imen of F901318 or posaconazole.
The combined PK-PD datasets (ie, plasma concentrations of 
F901318 and posaconazole and corresponding galactomannan 
data) were comodeled. The structural model shown below is for 
F901318. The same model was used for posaconazole except 
that the absorptive compartment was used to account for the 
oral administration of drug. 
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Figure 3. Pharmacokinetics and pharmacodynamics of voriconazole (A and B) and F901318 (C and D) in a dynamic model of acute invasive sinusitis caused by A flavus. 
The pharmacodynamic readout is the galactomannan index determined using the Platelia kit. The challenge strain was ATCC 204304. (A) Human-like pharmacokinetics of 
voriconazole; (B) pharmacodynamics of voriconazole; (C) human-like pharmacokinetics of F901318; (D) pharmacodynamics of F901318. A minimum blood plasma concentration 
(Cmin) of voriconazole of approximately 2 mg/L is required to suppress galactomannan. A Cmin of 0.3 of F901318 (and a Cmin:minimum inhibitory concentration of approximately 
10) is required to completely suppress galactomannan.
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Y (2) X (3)=
The system parameters and their units are as follows: R [1] rep-
resents the i.v. injection of F901318. SCL (L/h) is the clearance of 
drug from the central compartment; V (L) is the volume of the 
central compartment; Kcp (h−1) and Kpc (h−1) are the first-or-
der intercompartmental rate constants. Kgmax (GM/h) and 
kkillmax (GM/h) are the maximal rates of fungal growth and 
drug-induced kill, respectively. Popmax (GM) is the maximum 
theoretical fungal density. C50g (mg/L) and C50k (mg/L) are 
the concentrations of F901318 (or posaconazole) that induce 
half-maximal effects on growth and kill, respectively. Hg and Hk 
are the respective slope functions for growth and kill. The initial 
condition (GM; data not shown in the equations) is the fungal 
density immediately after inoculation, and it is estimated along 
with other parameters.
Equations 1 and 2 are standard PK equations that describe a 
2-compartment PK model with first-order clearance from the 
central compartment. The PD of F901318 (or posaconazole) 
against A flavus is described by Equation 3. The first and second 
output equations provides the time course of F901318 plasma 
concentrations and galactomannan, respectively.
RESULTS
Aspergillus flavus Strains and Antifungal Susceptibility Tests
The estimates for the MICs of F901318, voriconazole, and 
posaconazole for the 4 A flavus isolates used in this study are 
summarized in Table 1.
Static In Vitro Model of Acute Invasive Sinusitis
The sequence of conidial germination and hyphal invasion 
across the cellular bilayer is shown in Figure  1. Immediately 
after infection, conidia were observed on the epithelial surface 
(Figure  1A). Subsequently, hyphae were observed invading 
across the cellular bilayer and through the 3-µm perforations in 
the insert membrane as they transgressed from the nasal epithe-
lial surface through to the endothelial compartment.
Both voriconazole and F901318 caused a concentration-de-
pendent decline in galactomannan in the in vitro model of 
acute invasive sinusitis. This effect was most pronounced in the 
endothelial compartment where both agents caused near-max-
imal suppression of galactomannan (Figure 2). There was more 
strain-to-strain variability in the alveolar compartment. Neither 
voriconazole nor F901318 induced complete suppression of 
galactomannan in this compartment.
A B C
D E F
Figure 4. Histopathology of sinopulmonary aspergillosis. (A) Aspergillus flavus conidia and hyphae at and within the nasal epithelial surface 54 hours postinfection in a 
vehicle control; (B) section of the lung showing a fungal bronchopneumonia that was moderate-to-severe. There was evidence of vascular invasion in untreated controls 78 
hours postinoculation; (C) histopathological appearances after treatment with 20 mg/kg posaconazole; (D–F) histopathological appearances in mice receiving F901318 24 mg/
kg q24h, 8 mg/kg q8h, and 15 mg/kg q8h, respectively, which show a decline in fungal elements. Scale bar, 60 µm.
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Pharmacokinetics and Pharmacodynamic of Voriconazole and F901318 in 
the In Vitro Model of Acute Invasive Sinusitis
The simulated human PKs and the time-course of circulating 
galactomannan in response to voriconazole and F901318 are 
shown in Figure 3. Results from the ATCC strain were represen-
tative of the PD relationships of both voriconazole and F901318 
against other strains of A flavus (data from other strains are shown 
in Supplementary Data). In all untreated circuits, there was a 
progressive rise in galactomannan after 48 hours (Figure 3). The 
kinetics of galactomannan in control circuits for voriconazole and 
F901318 were similar, suggesting that the different pump speeds 
did not affect the respective PD of the 2 agents. There was an 
exposure-dependent decline in galactomannan induced by both 
voriconazole and F901318. A Cmin of voriconazole and F901318 
of approximately 2 mg/L and 0.3 mg/L, respectively, resulted in 
complete suppression of circulating galactomannan.
Histopathological Studies
Relatively scant hyphal elements were evident in the nasal cav-
ity at all time points and when present only superficial invasion 
was observed (Figure 4). In contrast, in the lung, there was a 
florid multifocal fungal bronchopneumonia that became pro-
gressively more extensive throughout the experimental period. 
At 78 hours postinoculation, the infection was fulminant and 
characterized by severe necrosis, hemorrhage, edema, necro-
tizing vasculitis, vascular invasion, and thrombosis. Elongating 
hyphae were abundant and consistently observed invading 
blood vessels (Figure 4B).
At 78 hours postinoculation, the appearances of F901318 
24  mg/kg Q24 were significantly worse than those observed 
with 8 mg/kg Q8 and 15 mg/kg Q8. No fungal organisms were 
identified in 2 of 3 animals in the F901318 15 mg/kg Q8 dose 
group, and only mild infection was found in a third mouse 
(Figure 4F).
In Vivo Pharmacodynamics of F901318
F901318 induced a decline in circulating galactomannan in 
mice with sinopulmonary aspergillosis. Near-maximal reduc-
tion was observed in mice receiving 15  mg/kg q8h for all 4 
challenge strains. The use of 24 mg/kg per day was less effective 
than 8 mg/kg q8h, which is consistent with previous observa-
tions that F901318 exhibits time-dependent antifungal activ-
ity. The relationship between Cmin:MIC and GM at 78 hours as 
well as Cmin:MIC and area under GM time curve is shown in 
Figure  5A and B. The Cmin:MIC values of 9–19 (mean 13.38) 
induced a decline in galactomannan that matched that induced 
by a posaconazole AUC of 47 mg*h/L.
Survival Studies
There was a drug exposure-dependent prolongation in survival 
for mice receiving F901318 (see Supplementary Data). For all 
4 strains, Cmin:MIC was highly predictive of survival (HR  <1 
and P values <<.01). For F901318, each 1-unit rise in Cmin:MIC 
resulted in a ~6%–10% (95% confidence interval [CI], 15%–
2%) increase in the probability of survival. For posaconazole, 
each 1-unit rise in AUC resulted in a ~4% (95% CI, 6%–2%) 
increase in the probability of survival. Plots of the HR as a func-
tion of the Cmin:MIC values for F901318 are shown in Figure 6. 
For each strain, the HR dropped below 1 (ie, caused prolonga-
tion of survival compared with controls) with Cmin:MIC values 
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Figure 5. In vivo pharmacokinetic-pharmacodynamic relationships of F901318 
and posaconazole against Aspergillus flavus. (A) Minimum blood plasma concen-
tration:minimum inhibitory concentration (Cmin:MIC) versus the area under galac-
tomannan-time curve for the 4 A flavus strains; (B) relationship between Cmin:MIC 
and the predicted Galactomannan (GM) (as determined by the Platelia kit) at 78 
hours for 4 A flavus strains; (C) relationship between the posaconazole area under 
the curve and both the predicted GM at 78 hours (solid squares) and area under the 
galactomannan-time curve (solid triangles).
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of approximately 10. For posaconazole, the HR was <1 after an 
AUC of approximately 40 mg*h/L.
DISCUSSION
F901318 and the orotomides have the potential to address cur-
rent limitations of modern systemic antifungal therapy. These 
new inhibitors of pyrimidine synthesis have broad-spectrum anti-
mould activity and specific broad-spectrum anti-Aspergillus activ-
ity that extends to triazole-resistant strains [17, 18, 30]. F901318 
is orally bioavailable, making it potentially suitable for the lon-
ger-term consolidation therapy. The single and multiple ascending 
dose (SAD and MAD) Phase I studies are complete as is the oral 
dosing program (ClinicalTrials.gov identifiers: NCT02142153, 
NCT02342574, NCT02394483, and NCT02737371) [18]. Phase II 
studies in a variety of clinical contexts are planned and will com-
mence shortly. Invariably, patients with invasive disease caused by 
A flavus will be enrolled in these studies.
F901318 has potent in vitro activity against A flavus with a 
modal MIC of 0.03 mg/L. Aspergillus flavus is the second most 
frequent species causing invasive aspergillosis and is the lead-
ing cause of acute invasive fungal sinusitis [7, 31]. A detailed 
understanding of the PD of F901318 against this pathogen 
ensures that regimens for clinical trials are derisked as far as 
possible. We developed in vitro and in vivo PD models to sim-
ulate human disease caused by A flavus. Human nasal epithelial 
cells were used to model the interaction of the relatively larger 
conidia of A flavus with the upper respiratory tract. These mod-
els proved a rigorous test for voriconazole (the in vitro models) 
and posaconazole (the murine model). In the dynamic in vitro 
model, a Cmin of voriconazole of 2 mg/L was required to sup-
press galactomannan, which is consistent with a large body of 
preclinical and clinical evidence [32, 33]. In the murine model, 
a clinically relevant exposure of posaconazole only resulted in 
relatively modest antifungal activity with a 25% reduction in the 
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Figure 6. Predictions from the Cox models fitted to the survival data from mice infected with various Aspergillus flavus strains, treated with F901318 for 3 days, and then 
observed for 7 more days. The solid line is the model estimate for each strain, and the gray-shaded area represents the 95% confidence interval. The F901318 minimum 
blood plasma concentration:minimum inhibitory concentration (Cmin:MIC) that results in a hazard ratio (HR) <1 is consistently approximately 10. For comparative purposes, a 
posaconazole area under the curve of approximately 40 mg.h/L results in an HR of <1.
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area under the galactomannan-time curve induced by an AUC 
of 47 mg*h/L.
We have recently described the PD of F901318 against A 
fumigatus, and we demonstrated that this compound exhibits 
time-dependent antifungal activity [27]. The Cmin:MIC is the PD 
index that best links drug exposure with the observed antifun-
gal effect. The principal task of this PD study is to determine 
the magnitude of the Cmin:MIC that is likely to be relevant for 
humans with invasive disease caused by A flavus. The different 
models and endpoints provided largely concordant information 
on the PD of F901318 for both A fumigatus and A flavus. The 
dynamic in vitro model with human-like PK suggests that an 
Cmin:MIC of approximately 10 is required to suppress circulat-
ing galactomannan and provide an effect that is comparable to 
voriconazole. The Cmin:MIC values of approximately 13 and 10 
result in comparable antifungal activity to posaconazole when 
assessed by galactomannan and survival, respectively. These 
drug exposures also result in near complete histopathological 
clearance of the lung with appearances that were comparable to 
posaconazole.
There are several aspects of the design of this program that 
deserve emphasis. The first is the importance of a positive con-
trol to benchmark the PD. We choose 2 agents for which there 
is a detailed understanding of the PD against Aspergillus spp. 
A  Cmin of voriconazole of 1–2  mg/L is required for optimal 
clinical outcomes, and it was required in the dynamic model of 
acute invasive sinusitis to achieve suppression of galactoman-
nan. Benchmarking enables experimental findings from models 
that are affected by the nuances of experimental design to be 
placed in a clinical context. We also used more than 1 experi-
mental model, challenge strain, and model readout to estimate 
the PD of F901318. Such an approach provides confidence in 
conclusions from preclinical models and accounts for the PD 
variability that is often marked.
CONCLUSIONS
F901318 has potent in vitro activity against A flavus and is 
highly active in both in vitro and in vivo models that are 
faithful mimics of invasive human disease. Regimens of 
F901318 for Phase II and III clinical trials must be at least as 
effective as other licensed antifungal agents. In this regard, 
these PD studies provided the basis for selection of regimens 
for further study in patients with invasive aspergillosis caused 
by A flavus.
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Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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